Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 266 of 6351
-
Immunotherapy combo aims to stop hodgkin lymphoma relapse after transplant
Disease control OngoingThis phase II trial studies how well nivolumab and brentuximab vedotin work after stem cell transplant in treating patients with high-risk classical Hodgkin lymphoma that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibo…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Immune boosting duo takes on rare throat cancer
Disease control OngoingThe purpose of this study is to test the hypothesis that a combined Immuno-Oncology (IO) strategy would see efficacy in a virally driven cancer like Nasopharyngeal Carcinoma (NPC). Hence, this is a combination study of nivolumab and ipilimumab in Epstein-Barr virus (EBV) driven n…
Phase 2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Could High-Dose vitamin c boost brain cancer treatment?
Disease control OngoingThis clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will receive high-dose ascorbate in addition to the standard treatment.
Phase 2 • Sponsor: Bryan Allen • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Combination therapy targets aggressive lymphoma in CLL patients
Disease control OngoingThis research study is evaluating the combination of a study drug, venetoclax, and a standard chemotherapy regimen, R-EPOCH or R-CHOP, as a possible treatment for Richter's Syndrome. The drugs involved in this study are: * Venetoclax * R-EPOCH: * Rituximab * Etoposide * …
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Could a sleep drug shield older hearts from post-surgery delirium?
Disease control CompletedThis study aims to determine whether, compared with placebo, the nighttime administration of a intravenous dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in extubated post-cardiac surgical patients.
Phase 2/3 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New combo therapy aims to stall returning prostate cancer
Disease control CompletedThis is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.
Phase 3 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Fat graft may mend heart scars after a heart attack
Disease control CompletedThe purpose of this trial is to evaluate the efficacy of a pericardial adipose graft transposition (Adipose Graft Trasposition Procedure, AGTP) for the improvement of cardiac function in patients with a chronic myocardial infarction. Preclinical studies in the porcine model of my…
Sponsor: Antoni Bayés Genís • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Pre-Surgery antibody boost prostate cancer outcomes?
Disease control OngoingThis study evaluates the safety, anti-tumor effect, and immunogenicity of Enoblituzumab given before radical prostatectomy. All patients will receive Enoblituzumab for 6 weekly doses beginning 50 days prior to radical prostatectomy.
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New hope for CLL: acalabrutinib takes on standard therapy in major trial
Disease control OngoingThis study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).
Phase 3 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New transplant method aims to reduce complications in bone marrow failure patients
Disease control OngoingThis is a single arm pilot study using TCR alpha/beta+ T cell-depleted peripheral blood stem cells (PBSC) from closely matched unrelated donors or partially matched/haploidentical related donors for hematopoietic stem cell transplant (HSCT) in patients with acquired and inherited…
Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Triple-Drug attack aims to wipe out Hard-to-Treat leukemia
Disease control OngoingThis phase II trial studies how well atezolizumab, obinutuzumab, and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma or Richter syndrome that has come back (recurrent) or does not respond to treatment (refractory). Immunotherap…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New combo therapy shows promise for tough brain tumors
Disease control CompletedThis study is a phase I/II, national, multicenter, open-label study starting with a Phase I part followed by a Phase II part. The phase I part of the study aims to evaluate the safety of the association of hypofractionated stereotactic radiation therapy (hFSRT) and the anti-PD-L…
Phase 1/2 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Smartphone sensors may predict bipolar mood swings before they strike
Disease control CompletedBipolar disorders are severe chronic disorders, marked by recurrent episodes of depression and (hypo)mania. The disorder usually emerges in early adulthood and tends to have a highly unpredictable course. Prevention of these episodes is essential, as they are associated with mark…
Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can an immune booster before surgery beat lung cancer?
Disease control CompletedBased on the efficacy of immunotherapies in advanced disease with a reasonable safety profile/tolerability we could hypothesize that, immunotherapy should work best in the situation of minimal residual disease, Two clinical trials are ongoing to test the role of immunotherapeutic…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Triple threat: new combo therapy targets Hard-to-Treat melanoma
Disease control OngoingThis phase II trial studies the side effects and how well nivolumab with trametinib and dabrafenib, or encorafenib and binimetinib work in treating patients with BRAF-mutated stage III-IV melanoma that has spread to other places in the body (metastatic) or cannot be removed by su…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
MRI-Guided radiation may improve cervical cancer treatment
Disease control CompletedPurpose of the study is to determine whether Image based brachytherapy is superior in terms of local control to Conventional radiograph based brachytherapy in locally advanced cervical cancers in a Phase III randomized setting.
Sponsor: Tata Memorial Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Could your own bone marrow repair a failing heart?
Disease control CompletedThis is a prospective, multi-center, randomized, controlled, patient- and evaluator-blinded study comparing treatment with the CardiAMP cell therapy to a sham control treatment. A roll-in phase with a maximum of 10 subjects may occur.
Phase 3 • Sponsor: BioCardia, Inc. • Aim: Disease control
Last updated Jun 26, 2026 19:03 UTC
-
HPV DNA test could slash cervical cancer deaths in High-Risk populations
Diagnosis Recruiting nowNearly 8 000 new cervical cancer cases are diagnosed in South Africa per year; many are still undiagnosed and about 50% of diagnosed cases succumb per year. Although the current prevalence of pre-cancer cervical disease is largely unknown, data from local studies suggest regional…
Sponsor: University of Pretoria • Aim: Diagnosis
Last updated Jul 09, 2026 00:00 UTC
-
Can Immune-Boosting drugs tame recurrent endometrial cancer?
Disease control OngoingThis research study is evaluating a drug called Avelumab alone and in combination with Talazoparib or Axitinib as a possible treatment for recurrent or metastatic endometrial cancer.
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New combo therapy shows promise for tough childhood leukemia
Disease control CompletedThis is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regim…
Phase 2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC